UK Edition
AdvertiseSubmit Company
Pharma JournalEvidence-Based Pharmaceutical Intelligence
CONSULTING, ADVISORY & MEDCOMMS

Inizio

Healthcare advisory, communications and commercial services group

Inizio logo

Inizio

Consulting, Advisory & MedCommsLondon, United Kingdom

Healthcare advisory, communications and commercial services group

Visit Website

About Inizio

Inizio is one of the largest purpose-built health advisory and communications networks in the world, formed in 2022 through the combination of several leading healthcare services businesses. The group operates across commercialisation, medical affairs, market access, patient engagement, and health communications, making it a rare single-source partner for the full lifecycle of pharmaceutical and biotech brand development.

A Purpose-Built Health Network

Rather than assembling a generic professional-services firm that happens to serve life sciences, Inizio was constructed with health as its only vertical. Its constituent companies, including Ashfield Engage, Evoke, and a range of specialist consulting and market access agencies, retained their individual brand identities while operating under shared leadership and infrastructure. This structure gives clients access to deep specialist capability within an integrated, globally coordinated network. The group employs tens of thousands of professionals across more than 30 countries, with headquarters in London, United Kingdom.

Commercial & Medical Engagement Services

The network's commercial and medical engagement arm supports pharmaceutical, biotech, and medtech manufacturers at every stage from pre-launch strategy through to late-lifecycle management. Services span field force deployment and outsourced sales teams, medical science liaison programmes, nurse and patient support services, and real-world evidence generation. On the communications side, Inizio's agencies work across medical education, scientific publications, public relations, and digital health content, serving both healthcare professional and patient audiences. Market access and health economics consulting complete the offering, addressing the payer and reimbursement challenges that determine whether innovative therapies actually reach patients at scale.

Inizio works across a broad range of therapy areas including oncology, rare diseases, immunology, neuroscience, cardiovascular medicine, and vaccines, reflecting the strategic priorities of the major pharmaceutical manufacturers that make up its core client base.

Further information is available at inizio.health.

Areas of Expertise

Medical AffairsMedical CommunicationsMedical EducationOncologyPatient Engagement

Services & Capabilities

Medical AffairsMedical CommunicationsMedical EducationOncologyPatient Engagement
Similar Companies

More in Consulting, Advisory & MedComms

A

Adelphi Communications

Adelphi Communications brings together real-world evidence, HEOR data, clinical evidence, and patient-reported outcomes into a unified, insight-led approach designed to optimise patient outcomes across the healthcare industry. The agency operates as a global medical communications partner, with offices in the UK and USA, and forms part of the wider Adelphi Group network of specialist healthcare consultancies. Capabilities and Approach At the core of Adelphi Communications' model is a highly collaborative way of working, grounded in knowledge and integrity. The agency's team draws from backgrounds in scientific and medical research, enabling it to develop creative, evidence-informed solutions to the complex challenges facing pharmaceutical and healthcare clients. Its work spans five principal disciplines, including scientific publications, congress support, digital medical education, and strategic medical communications planning. The agency's distinctive methodology lies in how it synthesises multiple data sources. By combining real-world evidence and HEOR data with clinical evidence and patient-reported outcomes, Adelphi Communications equips clients with a cohesive roadmap rather than fragmented analysis from isolated data streams. This evidence synthesis approach is particularly suited to healthcare companies navigating complex regulatory, market access, and clinical evidence environments. Adelphi Communications recruits across its UK and USA offices, offering professionals an environment with intensive on-the-job coaching and a structured programme of targeted training, making it a recognised employer within the medical communications sector. Further information is available at adelphicommunications.com.

View profile
A

AET

Part of the 100% family-owned Tiefenbacher Group, AET provides end-to-end pharmaceutical development and out-licensing solutions spanning more than 80 countries. With over 900 employees and its own laboratories and manufacturing facilities, the group builds efficient supply chains for marketing partners across every major regulated market, removing the full burden of development risk from commercial partners and accelerating their time-to-market. Out-Licensing Model and Core Capabilities AET's business model centres on developing, manufacturing, and registering pharmaceutical products before licensing them to partners worldwide. The portfolio covers value-added generic drug development, innovative medicines, and high-potent compounds, addressing three strategic pillars: better affordability, broader global availability, and genuine therapeutic improvement. From early formulation through regulatory dossier preparation, clinical supply, and multi-market registration, AET manages the entire product life cycle on behalf of its licensing partners. A recognised strength is the organisation's expertise in preparing best-in-class regulatory dossiers that support complex simultaneous launches across multiple jurisdictions. This capability has attracted some of the world's most trusted pharmaceutical brands as long-term partners, underpinned by consistent manufacturing quality and a scalable supply-chain infrastructure that handles both small-molecule and high-potency product categories. The Tiefenbacher Group's integrated model, combining in-house R&D, production, and regulatory affairs under one ownership structure, offers partners a single point of accountability from concept to commercial launch. AET's reach across diverse regulatory environments, from the European Medicines Agency to emerging-market agencies, makes it a capable partner for companies seeking to extend the commercial footprint of established or novel pharmaceutical products. Further information is available at aet.eu.

View profile
A

Alacrita Life Science Consulting

With a consulting network of more than 350 specialists spanning research and development and commercial functions, Alacrita Life Science Consulting provides strategic guidance and hands-on execution to biotech and pharmaceutical companies navigating drug development. The firm serves a broad client base that includes virtual and semi-virtual biotechs, established pharmaceutical companies, investors, technology transfer offices, and animal health companies. Alacrita's product development services span the full programme lifecycle, from opportunity mapping and preclinical strategy through clinical development, regulatory affairs, and CMC consulting. On the commercial side, the firm supports business planning, fundraising, interim chief medical officer engagements, and virtual biotech operations. Technology platform strategy, launch planning, and business development round out a service offering designed to cover the stages where specialist input most often determines programme outcomes. The firm also provides enterprise development services including due diligence, valuations, in-licensing and asset scouting, out-licensing, partnering and deal-making, and academic commercialisation. An investor services practice and expert witness capability further extend the scope available to clients. Alacrita's coverage extends across a wide range of product modalities, including antibodies and ADCs, cell therapies, gene therapies, radiopharmaceuticals, peptides and proteins, small molecules, and microbiome drugs. Disease area expertise encompasses oncology, CNS, immunology, haematology, respiratory, endocrine and metabolic conditions, fibrosis, and digestive and gastrointestinal disease, among others. Further information is available at alacrita.com.

View profile
AdvertisementTeksyte LTD

List Your Company

Showcase your company to thousands of pharma professionals.

Submit Listing

Advertise With Us

Reach decision-makers in the pharmaceutical industry.

Learn More

We use cookies and analytics to understand how the site is used and to keep the service free. Choose Accept All to allow this, or Essential Only to use just the cookies we need to keep the site working. You can change your choice any time in our Cookie Policy